N4-Cyclopropyl-N2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-5-(trifluoromethyl)pyrimidine-2,4-diamine

ID: ALA4776497

PubChem CID: 118906068

Max Phase: Preclinical

Molecular Formula: C15H13F3N6

Molecular Weight: 334.31

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  FC(F)(F)c1cnc(Nc2cnc3[nH]ccc3c2)nc1NC1CC1

Standard InChI:  InChI=1S/C15H13F3N6/c16-15(17,18)11-7-21-14(24-13(11)22-9-1-2-9)23-10-5-8-3-4-19-12(8)20-6-10/h3-7,9H,1-2H2,(H,19,20)(H2,21,22,23,24)

Standard InChI Key:  TUASMCDFYZNBEE-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 27  0  0  0  0  0  0  0  0999 V2000
   26.7348   -9.5875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.7336  -10.4071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4417  -10.8160    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.1513  -10.4066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1485   -9.5839    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.4399   -9.1787    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.0270   -9.1791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.0268   -8.3619    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   25.3194   -9.5879    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   25.3164   -8.7704    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   26.0256  -10.8151    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.8597  -10.8141    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.8610  -11.6313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1526  -12.0394    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1535  -12.8558    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.5674  -12.0350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.0249  -11.6323    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.6167  -12.3419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.4339  -12.3426    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.5758  -12.8482    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.8650  -13.2669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0435  -14.0723    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.8647  -14.1515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.1936  -13.3949    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  1  7  1  0
  7  8  1  0
  7  9  1  0
  7 10  1  0
  2 11  1  0
  4 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 21  2  0
 20 16  2  0
 16 13  1  0
 11 17  1  0
 18 17  1  0
 19 18  1  0
 17 19  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  2  0
 24 20  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4776497

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 334.31

Molecular Weight (Monoisotopic): 334.1154

AlogP: 3.69

#Rotatable Bonds: 4

Polar Surface Area: 78.52

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.19

CX Basic pKa: 4.25

CX LogP: 2.83

CX LogD: 2.83

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.68

Np Likeness Score: -1.36

References

1. Ren H,Bakas NA,Vamos M,Chaikuad A,Limpert AS,Wimer CD,Brun SN,Lambert LJ,Tautz L,Celeridad M,Sheffler DJ,Knapp S,Shaw RJ,Cosford NDP.  (2020)  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.,  63  (23): [PMID:33200929] [10.1021/acs.jmedchem.0c00873]

Source

Source(1):

• Scientific Literature